Novartis Looks To Take Its Diversity Show On The Road

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.